Review



active recombinant aurka protein  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc active recombinant aurka protein
    (A) Effect of gossypin on EGF-induced activation of various signaling proteins in JB6 cells. Serum-starved (0.1% FBS; 48 h) JB6 cells were treated with various doses of gossypin for 2 h followed by treatment with EGF for 30 min. (B) Effect of gossypin on various signaling proteins in HGC27 gastric cancer cells. Cells were treated with gossypin and then signaling pathway proteins were detected by Western blotting. (C) Gossypin inhibits phosphorylation of histone H3 in AGS gastric cancer cells. Cells were treated with gossypin for 24 h and detected by immunofluorescence assay. Red color indicates phosphorylated histone H3 at serine 10 and blue color shows DAPI. (D-E) Gossypin suppresses <t>AURKA</t> and RSK2 kinase activity in a dose-dependent manner. The effect of gossypin on AURKA or RSK2 activity was assessed by an in vitro kinase assay using AURKA (active, 200 ng) and MBP (AURKA substrate, 400 ng) or RSK2 (active, 200 ng) and ATF1 (RSK2 substrate, 300 ng) proteins. The effect of gossypin on kinase activities was determined by Western blotting using an antibody to detect phosphorylated serine and threonine. Band density was measured using the Image J (NIH) software program. For all data, similar results were obtained from 3 independent experiments.
    Active Recombinant Aurka Protein, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/active recombinant aurka protein/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    active recombinant aurka protein - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "Gossypin inhibits gastric cancer growth by direct targeting AURKA and RSK2"

    Article Title: Gossypin inhibits gastric cancer growth by direct targeting AURKA and RSK2

    Journal: Phytotherapy research : PTR

    doi: 10.1002/ptr.6253

    (A) Effect of gossypin on EGF-induced activation of various signaling proteins in JB6 cells. Serum-starved (0.1% FBS; 48 h) JB6 cells were treated with various doses of gossypin for 2 h followed by treatment with EGF for 30 min. (B) Effect of gossypin on various signaling proteins in HGC27 gastric cancer cells. Cells were treated with gossypin and then signaling pathway proteins were detected by Western blotting. (C) Gossypin inhibits phosphorylation of histone H3 in AGS gastric cancer cells. Cells were treated with gossypin for 24 h and detected by immunofluorescence assay. Red color indicates phosphorylated histone H3 at serine 10 and blue color shows DAPI. (D-E) Gossypin suppresses AURKA and RSK2 kinase activity in a dose-dependent manner. The effect of gossypin on AURKA or RSK2 activity was assessed by an in vitro kinase assay using AURKA (active, 200 ng) and MBP (AURKA substrate, 400 ng) or RSK2 (active, 200 ng) and ATF1 (RSK2 substrate, 300 ng) proteins. The effect of gossypin on kinase activities was determined by Western blotting using an antibody to detect phosphorylated serine and threonine. Band density was measured using the Image J (NIH) software program. For all data, similar results were obtained from 3 independent experiments.
    Figure Legend Snippet: (A) Effect of gossypin on EGF-induced activation of various signaling proteins in JB6 cells. Serum-starved (0.1% FBS; 48 h) JB6 cells were treated with various doses of gossypin for 2 h followed by treatment with EGF for 30 min. (B) Effect of gossypin on various signaling proteins in HGC27 gastric cancer cells. Cells were treated with gossypin and then signaling pathway proteins were detected by Western blotting. (C) Gossypin inhibits phosphorylation of histone H3 in AGS gastric cancer cells. Cells were treated with gossypin for 24 h and detected by immunofluorescence assay. Red color indicates phosphorylated histone H3 at serine 10 and blue color shows DAPI. (D-E) Gossypin suppresses AURKA and RSK2 kinase activity in a dose-dependent manner. The effect of gossypin on AURKA or RSK2 activity was assessed by an in vitro kinase assay using AURKA (active, 200 ng) and MBP (AURKA substrate, 400 ng) or RSK2 (active, 200 ng) and ATF1 (RSK2 substrate, 300 ng) proteins. The effect of gossypin on kinase activities was determined by Western blotting using an antibody to detect phosphorylated serine and threonine. Band density was measured using the Image J (NIH) software program. For all data, similar results were obtained from 3 independent experiments.

    Techniques Used: Activation Assay, Western Blot, Phospho-proteomics, Immunofluorescence, Activity Assay, In Vitro, Kinase Assay, Software

    (A) Modeling of gossypin binding with AURKA at the ATP binding pocket (left panel); and Ligand Interaction Diagram (LID) of the binding (upper right panel). (B) Modeling of gossypin binding with the N-terminal domain (NTD) at the ATP binding pocket of RSK2 (upper left panel) and LID of the binding (upper right panel). Modeling of gossypin binding with the C-terminal domain (CTD) at the ATP binding pocket of RSK2 (lower left panel) and LID of the binding (lower right panel). The AURKA, NTD RSK2 and CTD RSK2 structures are shown as ribbon representation and gossypin is shown as stick representation. LID legend is shown below. Gossypin directly binds to AURKA or RSK2 in (C) gastric cancer cell lysates or (D) as recombinant proteins. The recombinant proteins or cell lysates were incubated with gossypin-conjugated Sepharose 4B beads or with Sepharose 4B beads alone. The pulled down proteins were analyzed by Western blotting. For C and D, similar results were obtained from 3 independent experiments.
    Figure Legend Snippet: (A) Modeling of gossypin binding with AURKA at the ATP binding pocket (left panel); and Ligand Interaction Diagram (LID) of the binding (upper right panel). (B) Modeling of gossypin binding with the N-terminal domain (NTD) at the ATP binding pocket of RSK2 (upper left panel) and LID of the binding (upper right panel). Modeling of gossypin binding with the C-terminal domain (CTD) at the ATP binding pocket of RSK2 (lower left panel) and LID of the binding (lower right panel). The AURKA, NTD RSK2 and CTD RSK2 structures are shown as ribbon representation and gossypin is shown as stick representation. LID legend is shown below. Gossypin directly binds to AURKA or RSK2 in (C) gastric cancer cell lysates or (D) as recombinant proteins. The recombinant proteins or cell lysates were incubated with gossypin-conjugated Sepharose 4B beads or with Sepharose 4B beads alone. The pulled down proteins were analyzed by Western blotting. For C and D, similar results were obtained from 3 independent experiments.

    Techniques Used: Binding Assay, Recombinant, Incubation, Western Blot



    Similar Products

    active recombinant aurka protein  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc active recombinant aurka protein
    (A) Effect of gossypin on EGF-induced activation of various signaling proteins in JB6 cells. Serum-starved (0.1% FBS; 48 h) JB6 cells were treated with various doses of gossypin for 2 h followed by treatment with EGF for 30 min. (B) Effect of gossypin on various signaling proteins in HGC27 gastric cancer cells. Cells were treated with gossypin and then signaling pathway proteins were detected by Western blotting. (C) Gossypin inhibits phosphorylation of histone H3 in AGS gastric cancer cells. Cells were treated with gossypin for 24 h and detected by immunofluorescence assay. Red color indicates phosphorylated histone H3 at serine 10 and blue color shows DAPI. (D-E) Gossypin suppresses <t>AURKA</t> and RSK2 kinase activity in a dose-dependent manner. The effect of gossypin on AURKA or RSK2 activity was assessed by an in vitro kinase assay using AURKA (active, 200 ng) and MBP (AURKA substrate, 400 ng) or RSK2 (active, 200 ng) and ATF1 (RSK2 substrate, 300 ng) proteins. The effect of gossypin on kinase activities was determined by Western blotting using an antibody to detect phosphorylated serine and threonine. Band density was measured using the Image J (NIH) software program. For all data, similar results were obtained from 3 independent experiments.
    Active Recombinant Aurka Protein, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/active recombinant aurka protein/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    active recombinant aurka protein - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Effect of gossypin on EGF-induced activation of various signaling proteins in JB6 cells. Serum-starved (0.1% FBS; 48 h) JB6 cells were treated with various doses of gossypin for 2 h followed by treatment with EGF for 30 min. (B) Effect of gossypin on various signaling proteins in HGC27 gastric cancer cells. Cells were treated with gossypin and then signaling pathway proteins were detected by Western blotting. (C) Gossypin inhibits phosphorylation of histone H3 in AGS gastric cancer cells. Cells were treated with gossypin for 24 h and detected by immunofluorescence assay. Red color indicates phosphorylated histone H3 at serine 10 and blue color shows DAPI. (D-E) Gossypin suppresses AURKA and RSK2 kinase activity in a dose-dependent manner. The effect of gossypin on AURKA or RSK2 activity was assessed by an in vitro kinase assay using AURKA (active, 200 ng) and MBP (AURKA substrate, 400 ng) or RSK2 (active, 200 ng) and ATF1 (RSK2 substrate, 300 ng) proteins. The effect of gossypin on kinase activities was determined by Western blotting using an antibody to detect phosphorylated serine and threonine. Band density was measured using the Image J (NIH) software program. For all data, similar results were obtained from 3 independent experiments.

    Journal: Phytotherapy research : PTR

    Article Title: Gossypin inhibits gastric cancer growth by direct targeting AURKA and RSK2

    doi: 10.1002/ptr.6253

    Figure Lengend Snippet: (A) Effect of gossypin on EGF-induced activation of various signaling proteins in JB6 cells. Serum-starved (0.1% FBS; 48 h) JB6 cells were treated with various doses of gossypin for 2 h followed by treatment with EGF for 30 min. (B) Effect of gossypin on various signaling proteins in HGC27 gastric cancer cells. Cells were treated with gossypin and then signaling pathway proteins were detected by Western blotting. (C) Gossypin inhibits phosphorylation of histone H3 in AGS gastric cancer cells. Cells were treated with gossypin for 24 h and detected by immunofluorescence assay. Red color indicates phosphorylated histone H3 at serine 10 and blue color shows DAPI. (D-E) Gossypin suppresses AURKA and RSK2 kinase activity in a dose-dependent manner. The effect of gossypin on AURKA or RSK2 activity was assessed by an in vitro kinase assay using AURKA (active, 200 ng) and MBP (AURKA substrate, 400 ng) or RSK2 (active, 200 ng) and ATF1 (RSK2 substrate, 300 ng) proteins. The effect of gossypin on kinase activities was determined by Western blotting using an antibody to detect phosphorylated serine and threonine. Band density was measured using the Image J (NIH) software program. For all data, similar results were obtained from 3 independent experiments.

    Article Snippet: The active recombinant AURKA (300 ng) or RSK2 (200 ng) protein was mixed with different concentrations of gossypin in reaction buffer (Cell Signaling Technology) and incubated at room temperature for 15 min.

    Techniques: Activation Assay, Western Blot, Phospho-proteomics, Immunofluorescence, Activity Assay, In Vitro, Kinase Assay, Software

    (A) Modeling of gossypin binding with AURKA at the ATP binding pocket (left panel); and Ligand Interaction Diagram (LID) of the binding (upper right panel). (B) Modeling of gossypin binding with the N-terminal domain (NTD) at the ATP binding pocket of RSK2 (upper left panel) and LID of the binding (upper right panel). Modeling of gossypin binding with the C-terminal domain (CTD) at the ATP binding pocket of RSK2 (lower left panel) and LID of the binding (lower right panel). The AURKA, NTD RSK2 and CTD RSK2 structures are shown as ribbon representation and gossypin is shown as stick representation. LID legend is shown below. Gossypin directly binds to AURKA or RSK2 in (C) gastric cancer cell lysates or (D) as recombinant proteins. The recombinant proteins or cell lysates were incubated with gossypin-conjugated Sepharose 4B beads or with Sepharose 4B beads alone. The pulled down proteins were analyzed by Western blotting. For C and D, similar results were obtained from 3 independent experiments.

    Journal: Phytotherapy research : PTR

    Article Title: Gossypin inhibits gastric cancer growth by direct targeting AURKA and RSK2

    doi: 10.1002/ptr.6253

    Figure Lengend Snippet: (A) Modeling of gossypin binding with AURKA at the ATP binding pocket (left panel); and Ligand Interaction Diagram (LID) of the binding (upper right panel). (B) Modeling of gossypin binding with the N-terminal domain (NTD) at the ATP binding pocket of RSK2 (upper left panel) and LID of the binding (upper right panel). Modeling of gossypin binding with the C-terminal domain (CTD) at the ATP binding pocket of RSK2 (lower left panel) and LID of the binding (lower right panel). The AURKA, NTD RSK2 and CTD RSK2 structures are shown as ribbon representation and gossypin is shown as stick representation. LID legend is shown below. Gossypin directly binds to AURKA or RSK2 in (C) gastric cancer cell lysates or (D) as recombinant proteins. The recombinant proteins or cell lysates were incubated with gossypin-conjugated Sepharose 4B beads or with Sepharose 4B beads alone. The pulled down proteins were analyzed by Western blotting. For C and D, similar results were obtained from 3 independent experiments.

    Article Snippet: The active recombinant AURKA (300 ng) or RSK2 (200 ng) protein was mixed with different concentrations of gossypin in reaction buffer (Cell Signaling Technology) and incubated at room temperature for 15 min.

    Techniques: Binding Assay, Recombinant, Incubation, Western Blot